Achieve Life Sciences (ACHV) Q2 2023: ORCA3 Delivers 4–6x Quit Odds, NDA Path and Partnering in Focus
ACHV’s pivotal ORCA3 results cement cytosinicline’s profile as a best-in-class smoking cessation candidate, with odds ratios four to six times higher than placebo and a benign safety profile. The company’s capital raise and debt extension secure a cash runway into late 2024, supporting regulatory and commercial readiness. With NDA submission targeted for H1 2024 and global partnering discussions underway, Achieve’s trajectory hinges on execution, FDA feedback, and market access strategy.
Summary
- ORCA3 Data Validates Efficacy: Cytosinicline demonstrated 4–6x greater quit odds versus placebo, outpacing legacy treatments.
- Regulatory and Commercial Readiness: NDA timeline, supply chain buildup, and global partnering are at the center of execution.
- Capital and Focus Secure Near-Term Runway: Cash raise and expense discipline provide time to deliver on inflection milestones.
Business Overview
Achieve Life Sciences is a clinical-stage biopharmaceutical company focused on developing cytosinicline, a novel, plant-based therapy targeting nicotine addiction. The company’s core business is advancing cytosinicline through late-stage clinical trials and regulatory approval for smoking cessation, with expansion plans into e-cigarette (vaping) cessation. Revenue will derive from future product sales, commercial partnerships, and potential licensing agreements, with the U.S. and global nicotine dependence markets as primary targets.
Performance Analysis
Q2 2023 marked a transformative period for Achieve, driven by the ORCA3 Phase 3 trial, which replicated the strong efficacy seen in ORCA2 and validated cytosinicline’s differentiated profile. The trial’s 12-week treatment arm reported quit rates above 30 percent, with odds ratios between four and six, significantly exceeding benchmarks from historical Chantix, Bupropion, and NRT studies. At 24 weeks, quit rates remained above 20 percent, with sustained odds ratios of five to six, underscoring durable efficacy.
Complementing efficacy, cytosinicline’s safety profile continues to stand out, with only 2.9 percent discontinuation due to adverse events and no treatment-related serious adverse events in the vaping cessation trial. Financially, Achieve reduced its net loss to $8.2 million for the quarter and improved its cash position to $25.1 million, following a $16.5 million capital raise and extension of its Silicon Valley Bank loan maturity to December 2024. Operating expenses are expected to decline in the second half as major trials wind down, though NDA-preparation costs will partially offset this benefit.
- ORCA3 Replicates and Exceeds Prior Benchmarks: Efficacy and safety data support regulatory and commercial value claims.
- Expense Discipline as Trials Conclude: Lower R&D spend as pivotal trials complete, with focus shifting to regulatory and supply chain activities.
- Cash Runway Extended Into Late 2024: Recent raise and debt restructuring provide time to reach major milestones.
With both clinical and financial levers advancing, Achieve is positioned to deliver on its NDA timeline and prepare for potential launch, but execution risk remains as regulatory and commercial hurdles approach.
Executive Commentary
"The first half of 2023 has seen the culmination of our ambitions to bring the first smoking cessation product to market in nearly 20 years take a meaningful step forward."
John Bincich, Chief Executive Officer
"We believe our current cash balance is sufficient to provide us runway into the second half of 2024."
Jerry Wan, Principal Accounting Officer
Strategic Positioning
1. Regulatory Pathway and NDA Submission
Achieve’s primary focus is the NDA (New Drug Application) submission for cytosinicline in smoking cessation, targeted for the first half of 2024. All remaining clinical studies (renal impairment, QT interval, PK) are expected to complete by year-end, with the pre-NDA FDA meeting set for Q4 2023. This meeting will clarify regulatory expectations and refine submission timing, representing a pivotal risk gate for the program.
2. Commercial Readiness and Supply Chain
Significant investment is being made in CMC (Chemistry, Manufacturing, and Controls) and inventory buildup with SoPharma, ensuring three to four years of launch supply by year-end and continued stockpiling into 2024. Readiness for FDA inspection is a critical operational focus, with management confident but vigilant about regulatory standards.
3. Partnering and Global Expansion
Achieve is actively engaged in partnering discussions, prioritizing a single global partner with strong U.S. capabilities, but remains open to regional deals if necessary. Management sees substantial interest from Asia and other ex-U.S. markets, but is holding for a larger transaction to maximize value and leverage global reach.
4. Market Differentiation and Unmet Need
Cytosinicline’s efficacy, short-course option, and benign safety profile position it as a best-in-class therapy in a market with no new FDA-approved agents in nearly two decades. Political and reimbursement tailwinds, including ACA-mandated coverage, further support rapid uptake if approved.
5. Pipeline and Indication Expansion
The company is preparing to expand into vaping cessation, with ORCA V1 data showing 2.6x quit odds and no serious adverse events. Pediatric indications are a longer-term ambition, with initial focus on adult e-cigarette users.
Key Considerations
ACHV’s Q2 was defined by clinical validation, regulatory progress, and operational discipline, but the next 12 months will test its ability to deliver on multiple fronts.
Key Considerations:
- Regulatory Milestone Concentration: The pre-NDA FDA meeting and NDA acceptance are binary risk events that will determine near-term value realization.
- Manufacturing and Supply Chain Execution: FDA inspection readiness and multi-year inventory buildup are essential for launch viability and partnership leverage.
- Partnering Optionality vs. Dilution: Timing and structure of partnership(s) will drive capital needs, strategic flexibility, and potential for global scale.
- Market Access and Reimbursement: ACA coverage and lack of branded competition create a favorable environment, but payer dynamics and prescriber adoption must be watched.
- Expansion Beyond Smoking Cessation: Vaping indication offers a second growth vector, but regulatory and clinical investment will be required post-NDA.
Risks
Regulatory hurdles remain the primary risk, with FDA feedback on the NDA and manufacturing inspection representing potential gating factors. Execution risk around supply chain, inventory buildup, and partner negotiations could impact launch timing and scale. Competitive landscape may shift if new entrants or generics accelerate development, and payer pushback could affect pricing or access. Any delays in clinical or regulatory timelines could pressure cash runway and require further dilution or partnership concessions.
Forward Outlook
For Q3 and Q4 2023, Achieve expects to:
- Complete all remaining NDA-supporting clinical studies (renal impairment, QT, PK)
- Hold pre-NDA meeting with FDA in Q4
- Continue inventory buildup and CMC readiness for launch
For full-year 2023, management reiterated:
- NDA submission targeted for H1 2024
- Cash runway into the second half of 2024
Management highlighted that successful completion of clinical and CMC activities, positive FDA engagement, and progress in partnering discussions are the key milestones that will drive value and de-risk the story.
- FDA feedback and NDA acceptance will shape 2024 inflection
- Partnership outcome could alter capital needs and commercialization path
Takeaways
ACHV’s Q2 results and narrative reinforce cytosinicline’s best-in-class profile and clear regulatory path, but the company’s value realization depends on flawless execution and successful navigation of near-term regulatory and commercial hurdles.
- Clinical Validation: ORCA3 and ORCA V1 data position cytosinicline as a differentiated option for both smoking and vaping cessation, with efficacy and safety advantages over legacy agents.
- Operational and Financial Discipline: Expense control, capital raise, and supply chain buildup give Achieve a fighting chance to deliver on its NDA and partnering milestones without near-term dilution.
- Milestone-Driven Story: Investors should watch for FDA feedback, NDA submission, and partnership progress as the next major catalysts and risk gates.
Conclusion
Achieve enters a decisive period with clinical momentum, capital runway, and a clear regulatory agenda. Execution on NDA, manufacturing, and partnership fronts will determine whether cytosinicline can become the first new U.S. smoking cessation therapy in two decades and unlock broader nicotine addiction markets.
Industry Read-Through
ACHV’s progress signals renewed innovation potential in the smoking cessation and addiction treatment landscape, a market long dominated by legacy agents and generics. With cytosinicline’s efficacy and safety profile, payers and prescribers may finally have a differentiated alternative, potentially resetting expectations for new entrants. Success would validate the market opportunity for first-in-class addiction therapies and could spur M&A or licensing activity among larger pharma players facing patent cliffs and seeking pipeline diversification. The focus on vaping cessation also highlights the growing clinical and commercial importance of addressing e-cigarette dependence, an area with rising prevalence and limited treatment options.